# A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

> **NCT04278924** · PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 41 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** TAK-079

## Key facts

- **NCT ID:** NCT04278924
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2024-04-29
- **Final completion:** 2024-04-29
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278924, "A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04278924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*